Anixa Biosciences (ANIX) vs Quantum Cyber N.V. (QUCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Quantum Cyber N.V. (QUCY) has outperformed Anixa Biosciences (ANIX) over the past year, losing 28.9% versus a loss of 34.9%. Anixa Biosciences is the larger company by market cap ($92.8 million vs $92.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | QUCY |
|---|---|---|
| Share price | $2.67 | $1.06 |
| Market cap | $92.82M | $92.45M |
| 1-day change | -3.96% | -2.75% |
| YTD return | -14.42% | -5.36% |
| 1-year return | -34.88% | -28.86% |
| 5-year return | -38.48% | — |
| EPS (TTM) | $-0.32 | $-2.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $537.08K |
| Revenue growth (YoY) | — | -39.92% |
| Net income (latest FY) | $-10.93M | $-16.21M |
| Gross margin | — | 72.58% |
| Operating margin | — | -3004.97% |
| Net margin | — | -3018.31% |
| 52-week high | $5.46 | $4.93 |
| 52-week low | $2.32 | $0.30 |
| Distance from 52-week high | -51.10% | -78.50% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +265.17% | +749.06% |
| Average volume | 296.48K | 672.52K |
| Shares outstanding | 34.76M | 87.22M |
| Employees | 4 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Quantum Cyber N.V.
QUCY stock →Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
ANIX vs QUCY FAQ
Which is bigger, Anixa Biosciences or Quantum Cyber N.V.?
Anixa Biosciences (ANIX) is larger, with a market capitalization of $92.82M compared with $92.45M for Quantum Cyber N.V. (QUCY).
Which stock has performed better over the past year, ANIX or QUCY?
QUCY returned -28.86% over the past 12 months, compared with -34.88% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Quantum Cyber N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.